The
Fourth Henry Stewart One-Day Briefing on
Latest Thinking on
Attacking/Defending Patent Rights in the
U.S. Pharmaceutical and Biotechnology Markets
This
leading edge briefing, delivered by some of the subject’s most
knowledgeable experts, will take delegates through the law and practice
of defending their innovations and avoiding exclusive United States
marketing rights in the pharmaceutical and biotechnology industries.
It will consider how the law stands now, how it has been interpreted
by the FDA, FTC, PTO and the courts and how it is likely to be interpreted
in the future.
The
briefing will cover:
-
Regulatory exclusivity strategies under Hatch-Waxman, the Medicare Modernization Act and Bioshield-2
-
Discussion of the Supreme Court decision on the 271(e)(1) Safe Harbor: Merck v. Integra
-
Patent term extension strategies and opportunities
-
Strategies for ANDA filings and obtaining 180-day exclusivity
-
Coordinating worldwide patent litigation
-
Protecting your IP rights while avoiding antitrust litigation
The
strategies and tactics for both innovator and generic companies will
be illustrated throughout by reviews of current case law and the speakers
will discuss the implications of the possible outcomes of ongoing litigation
battles and legislative proposals.
For
everyone seeking to defend or challenge pharmaceutical or biotechnology
patents.
Full documentation will be provided to all delegates and adequate time set aside for questions and discussion.
Wednesday,
28 September 2005
Hilton San Francisco Fisherman's Wharf
San Francisco, CA